| Entry |
|
|---|
| Symbol |
BRAF, B-RAF1, B-raf, BRAF-1, BRAF1, NS7, RAFB1
|
|---|
| Name |
(RefSeq) B-Raf proto-oncogene, serine/threonine kinase
|
|---|
| KO |
| K04365 | B-Raf proto-oncogene serine/threonine-protein kinase [EC:2.7.11.1] |
|
|---|
| Organism |
|
|---|
| Pathway |
| hsa01521 | EGFR tyrosine kinase inhibitor resistance |
| hsa04270 | Vascular smooth muscle contraction |
| hsa04650 | Natural killer cell mediated cytotoxicity |
| hsa04810 | Regulation of actin cytoskeleton |
| hsa04914 | Progesterone-mediated oocyte maturation |
| hsa04928 | Parathyroid hormone synthesis, secretion and action |
| hsa05022 | Pathways of neurodegeneration - multiple diseases |
| hsa05208 | Chemical carcinogenesis - reactive oxygen species |
|
|---|
| Network |
|
|---|
| Element |
| N00001 | EGF-EGFR-RAS-ERK signaling pathway |
| N00002 | BCR-ABL fusion kinase to RAS-ERK signaling pathway |
| N00003 | Mutation-activated KIT to RAS-ERK signaling pathway |
| N00004 | Duplication or mutation-activated FLT3 to RAS-ERK signaling pathway |
| N00005 | Mutation-activated MET to RAS-ERK signaling pathway |
| N00006 | Amplified EGFR to RAS-ERK signaling pathway |
| N00007 | EML4-ALK fusion kinase to RAS-ERK signaling pathway |
| N00008 | RET fusion kinase to RAS-ERK signaling pathway |
| N00009 | TRK fusion kinase to RAS-ERK signaling pathway |
| N00011 | Mutation-activated FGFR3 to RAS-ERK signaling pathway |
| N00012 | Mutation-activated KRAS/NRAS to ERK signaling pathway |
| N00013 | Mutation-activated BRAF to ERK signaling pathway |
| N00014 | Mutation-activated EGFR to RAS-ERK signaling pathway |
| N00015 | PDGF-PDGFR-RAS-ERK signaling pathway |
| N00016 | PDGF-overexpression to RAS-ERK signaling pathway |
| N00018 | Amplified PDGFR to RAS-ERK signaling pathway |
| N00019 | FGF-FGFR-RAS-ERK signaling pathway |
| N00020 | Amplified FGFR to RAS-ERK signaling pathway |
| N00021 | EGF-ERBB2-RAS-ERK signaling pathway |
| N00022 | ERBB2-overexpression to RAS-ERK signaling pathway |
| N00023 | EGF-EGFR-PLCG-ERK signaling pathway |
| N00024 | Mutation-activated EGFR to PLCG-ERK signaling pathway |
| N00025 | EML4-ALK fusion kinase to PLCG-ERK signaling pathway |
| N00041 | EGFR-overexpression to RAS-ERK signaling pathway |
| N00077 | HRAS-overexpression to ERK signaling pathway |
| N00078 | Mutation-activated HRAS to ERK signaling pathway |
| N00215 | KITLG-KIT-RAS-ERK signaling pathway |
| N00216 | HGF-MET-RAS-ERK signaling pathway |
| N00217 | FLT3LG-FLT3-RAS-ERK signaling pathway |
| N00229 | TGFA-EGFR-RAS-ERK signaling pathway |
| N00230 | TGFA-overexpression to RAS-ERK signaling pathway |
| N00233 | IGF-IGF1R-RAS-ERK signaling pathway |
| N00235 | IGF2-overexpression to RAS-ERK signaling pathway |
| N00237 | IGF1R-overexpression to RAS-ERK signaling pathway |
| N00246 | HGF-overexpression to RAS-ERK signaling pathway |
| N00248 | MET-overexpression to RAS-ERK signaling pathway |
| N00252 | Amplified ERBB2 to RAS-ERK signaling pathway |
| N00259 | Amplified MET to RAS-ERK signaling pathway |
| N00276 | EGF-overexpression to RAS-ERK signaling pathway |
| N00277 | EREG-EGFR-RAS-ERK signaling pathway |
| N00278 | EREG-overexpression to RAS-ERK signaling pathway |
| N00279 | AREG-EGFR-RAS-ERK signaling pathway |
| N00280 | AREG-overexpression to RAS-ERK signaling pathway |
| N00367 | HPV E5 to EGFR-RAS-ERK signaling pathway |
| N00386 | HCMV gB to PDGFR-RAS-ERK signaling pathway |
| N00513 | Mutation-activated EGFR to RAS-ERK signaling pathway |
| N00518 | HCV Core to ERK signaling pathway |
| N00538 | Ca2+-PYK2-RAS-ERK signaling pathway |
| N00540 | HBV HBx to RAS-ERK signaling pathway |
| N00546 | CXCL12-CXCR4-PKC-ERK signaling pathaway |
| N00744 | IAV HA to ERK signaling pathway |
| N00994 | AGE-RAGE signaling pathway |
| N00996 | Mutation-caused aberrant Abeta to AGE-RAGE signaling pathway |
| N01062 | Mutation-activated MET to RAS-ERK signaling pathway |
| N01064 | Mutation-activated RET to RAS-ERK signaling pathway |
| N01119 | RAC/CDC42-PAK-ERK signaling pathway |
| N01343 | ACH-CHRN-RAS-ERK signaling pathway |
| N01344 | NNK/NNN to RAS-ERK signaling pathway |
| N01351 | E2-ER-RAS-ERK signaling pathway |
| N01352 | BPA to RAS-ERK signaling pathway |
| N01353 | E2 to RAS-ERK signaling pathway |
| N01354 | BPA to RAS-ERK signaling pathway |
| N01360 | P4-PR-RAS-ERK signaling pathway |
| N01361 | P4/MPA to PR-RAS-ERK signaling pathway |
| N01408 | Metals to RAS-ERK signaling pathway |
| N01592 | GF-RTK-RAS-ERK signaling pathway |
| N01598 | Regulation of GF-RTK-RAS-ERK signaling, MRAS-SHOC2-PP1 holophosphatase |
|
|---|
| Disease |
| H00014 | Non-small cell lung cancer |
| H00523 | Noonan syndrome and related disorders |
| H01512 | Langerhans cell histiocytosis |
| H01745 | Cardiofaciocutaneous syndrome |
| H02425 | Erdheim-Chester disease |
|
|---|
| Drug target |
|
|---|
| Brite |
KEGG Orthology (KO) [BR:hsa00001]
09130 Environmental Information Processing
09132 Signal transduction
04010 MAPK signaling pathway
673 (BRAF)
04012 ErbB signaling pathway
673 (BRAF)
04015 Rap1 signaling pathway
673 (BRAF)
04068 FoxO signaling pathway
673 (BRAF)
04024 cAMP signaling pathway
673 (BRAF)
04150 mTOR signaling pathway
673 (BRAF)
09140 Cellular Processes
09144 Cellular community - eukaryotes
04510 Focal adhesion
673 (BRAF)
09142 Cell motility
04810 Regulation of actin cytoskeleton
673 (BRAF)
09150 Organismal Systems
09151 Immune system
04650 Natural killer cell mediated cytotoxicity
673 (BRAF)
04062 Chemokine signaling pathway
673 (BRAF)
09152 Endocrine system
04910 Insulin signaling pathway
673 (BRAF)
04914 Progesterone-mediated oocyte maturation
673 (BRAF)
04928 Parathyroid hormone synthesis, secretion and action
673 (BRAF)
09153 Circulatory system
04270 Vascular smooth muscle contraction
673 (BRAF)
09156 Nervous system
04726 Serotonergic synapse
673 (BRAF)
04720 Long-term potentiation
673 (BRAF)
04730 Long-term depression
673 (BRAF)
04722 Neurotrophin signaling pathway
673 (BRAF)
09160 Human Diseases
09161 Cancer: overview
05200 Pathways in cancer
673 (BRAF)
05205 Proteoglycans in cancer
673 (BRAF)
05208 Chemical carcinogenesis - reactive oxygen species
673 (BRAF)
09162 Cancer: specific types
05210 Colorectal cancer
673 (BRAF)
05212 Pancreatic cancer
673 (BRAF)
05225 Hepatocellular carcinoma
673 (BRAF)
05226 Gastric cancer
673 (BRAF)
05214 Glioma
673 (BRAF)
05216 Thyroid cancer
673 (BRAF)
05221 Acute myeloid leukemia
673 (BRAF)
05220 Chronic myeloid leukemia
673 (BRAF)
05218 Melanoma
673 (BRAF)
05211 Renal cell carcinoma
673 (BRAF)
05219 Bladder cancer
673 (BRAF)
05215 Prostate cancer
673 (BRAF)
05213 Endometrial cancer
673 (BRAF)
05224 Breast cancer
673 (BRAF)
05223 Non-small cell lung cancer
673 (BRAF)
09172 Infectious disease: viral
05161 Hepatitis B
673 (BRAF)
05160 Hepatitis C
673 (BRAF)
09164 Neurodegenerative disease
05010 Alzheimer disease
673 (BRAF)
05022 Pathways of neurodegeneration - multiple diseases
673 (BRAF)
09165 Substance dependence
05034 Alcoholism
673 (BRAF)
09167 Endocrine and metabolic disease
04934 Cushing syndrome
673 (BRAF)
09176 Drug resistance: antineoplastic
01521 EGFR tyrosine kinase inhibitor resistance
673 (BRAF)
01522 Endocrine resistance
673 (BRAF)
09180 Brite Hierarchies
09181 Protein families: metabolism
01001 Protein kinases [BR:hsa01001]
673 (BRAF)
Enzymes [BR:hsa01000]
2. Transferases
2.7 Transferring phosphorus-containing groups
2.7.11 Protein-serine/threonine kinases
2.7.11.1 non-specific serine/threonine protein kinase
673 (BRAF)
Protein kinases [BR:hsa01001]
Serine/threonine kinases: TKL group
RAF family [OT]
673 (BRAF)
|
|---|
| SSDB |
|
|---|
| Motif |
|
|---|
| Other DBs |
|
|---|
| Structure |
|
|---|
| LinkDB |
|
|---|
| Position |
7:complement(140713328..140924929)
|
|---|
| AA seq |
766 aa
MAALSGGGGGGAEPGQALFNGDMEPEAGAGAGAAASSAADPAIPEEVWNIKQMIKLTQEH
IEALLDKFGGEHNPPSIYLEAYEEYTSKLDALQQREQQLLESLGNGTDFSVSSSASMDTV
TSSSSSSLSVLPSSLSVFQNPTDVARSNPKSPQKPIVRVFLPNKQRTVVPARCGVTVRDS
LKKALMMRGLIPECCAVYRIQDGEKKPIGWDTDISWLTGEELHVEVLENVPLTTHNFVRK
TFFTLAFCDFCRKLLFQGFRCQTCGYKFHQRCSTEVPLMCVNYDQLDLLFVSKFFEHHPI
PQEEASLAETALTSGSSPSAPASDSIGPQILTSPSPSKSIPIPQPFRPADEDHRNQFGQR
DRSSSAPNVHINTIEPVNIDDLIRDQGFRGDGGSTTGLSATPPASLPGSLTNVKALQKSP
GPQRERKSSSSSEDRNRMKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGDV
AVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHH
LHIIETKFEMIKLIDIARQTAQGMDYLHAKSIIHRDLKSNNIFLHEDLTVKIGDFGLATV
KSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYSNIN
NRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARS
LPKIHRSASEPSLNRAGFQTEDFSLYACASPKTPIQAGGYGAFPVH |
|---|
| NT seq |
2301 nt +upstreamnt +downstreamnt
atggcggcgctgagcggtggcggtggtggcggcgcggagccgggccaggctctgttcaac
ggggacatggagcccgaggccggcgccggcgccggcgccgcggcctcttcggctgcggac
cctgccattccggaggaggtgtggaatatcaaacaaatgattaagttgacacaggaacat
atagaggccctattggacaaatttggtggggagcataatccaccatcaatatatctggag
gcctatgaagaatacaccagcaagctagatgcactccaacaaagagaacaacagttattg
gaatctctggggaacggaactgatttttctgtttctagctctgcatcaatggataccgtt
acatcttcttcctcttctagcctttcagtgctaccttcatctctttcagtttttcaaaat
cccacagatgtggcacggagcaaccccaagtcaccacaaaaacctatcgttagagtcttc
ctgcccaacaaacagaggacagtggtacctgcaaggtgtggagttacagtccgagacagt
ctaaagaaagcactgatgatgagaggtctaatcccagagtgctgtgctgtttacagaatt
caggatggagagaagaaaccaattggttgggacactgatatttcctggcttactggagaa
gaattgcatgtggaagtgttggagaatgttccacttacaacacacaactttgtacgaaaa
acgtttttcaccttagcattttgtgacttttgtcgaaagctgcttttccagggtttccgc
tgtcaaacatgtggttataaatttcaccagcgttgtagtacagaagttccactgatgtgt
gttaattatgaccaacttgatttgctgtttgtctccaagttctttgaacaccacccaata
ccacaggaagaggcgtccttagcagagactgccctaacatctggatcatccccttccgca
cccgcctcggactctattgggccccaaattctcaccagtccgtctccttcaaaatccatt
ccaattccacagcccttccgaccagcagatgaagatcatcgaaatcaatttgggcaacga
gaccgatcctcatcagctcccaatgtgcatataaacacaatagaacctgtcaatattgat
gacttgattagagaccaaggatttcgtggtgatggaggatcaaccacaggtttgtctgct
accccccctgcctcattacctggctcactaactaacgtgaaagccttacagaaatctcca
ggacctcagcgagaaaggaagtcatcttcatcctcagaagacaggaatcgaatgaaaaca
cttggtagacgggactcgagtgatgattgggagattcctgatgggcagattacagtggga
caaagaattggatctggatcatttggaacagtctacaagggaaagtggcatggtgatgtg
gcagtgaaaatgttgaatgtgacagcacctacacctcagcagttacaagccttcaaaaat
gaagtaggagtactcaggaaaacacgacatgtgaatatcctactcttcatgggctattcc
acaaagccacaactggctattgttacccagtggtgtgagggctccagcttgtatcaccat
ctccatatcattgagaccaaatttgagatgatcaaacttatagatattgcacgacagact
gcacagggcatggattacttacacgccaagtcaatcatccacagagacctcaagagtaat
aatatatttcttcatgaagacctcacagtaaaaataggtgattttggtctagctacagtg
aaatctcgatggagtgggtcccatcagtttgaacagttgtctggatccattttgtggatg
gcaccagaagtcatcagaatgcaagataaaaatccatacagctttcagtcagatgtatat
gcatttggaattgttctgtatgaattgatgactggacagttaccttattcaaacatcaac
aacagggaccagataatttttatggtgggacgaggatacctgtctccagatctcagtaag
gtacggagtaactgtccaaaagccatgaagagattaatggcagagtgcctcaaaaagaaa
agagatgagagaccactctttccccaaattctcgcctctattgagctgctggcccgctca
ttgccaaaaattcaccgcagtgcatcagaaccctccttgaatcgggctggtttccaaaca
gaggattttagtctatatgcttgtgcttctccaaaaacacccatccaggcagggggatat
ggtgcgtttcctgtccactga |
|---|
